Login
$BLSM
$13.65 -$0.37 (2.64%) Live

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Source
Jingrong Jean Cui
President and CEO
Title from the Form 4 dated Aug 6, 2026
Jason A Keyes
Chief Financial Officer
Title from the Form 4 dated Aug 6, 2026
Yishan Li
Executive Chairman
Title from the Form 4 dated Aug 6, 2026
Vincent Paul Liptak
General Counsel
Title from the Form 4 dated Aug 6, 2026
Geoffrey Raymond Oxnard
Chief Medical Officer
Title from the Form 4 dated Aug 6, 2026

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

No proxy statement on record

Board of Directors comes from the company’s proxy statement. BlossomHill Therapeutics, Inc. has not filed one with the SEC.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. BlossomHill Therapeutics, Inc. has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support